Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy the TNT trial

Journal of the American College of Cardiology

Volumn 65, Issue 13, 2015, Pages 1286-1295

  Byun, Young Sup ^a,b   Lee, Jun Hee ^a,c   Arsenault, Benoit J ^d   Yang, Xiaohong ^b   Bao, Weihang ^e   Demicco, David ^e   Laskey, Rachel ^e   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Inje University College of Medicine   (South Korea)

^c Hallym University Medical Center   (South Korea)

^d LAVAL UNIVERSITY   (Canada)

^e PFIZER INC   (United States)

Author keywords

Atherosclerosis; Biomarker; Coronary heart disease; Inflammatory; Oxidation specific epitope

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; BIOLOGICAL MARKER; EPITOPE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; AGED; BLOOD; CARDIOVASCULAR DISEASES; CORONARY DISEASE; MIDDLE AGED; OXIDATION REDUCTION REACTION; RISK FACTOR;

AGED; APOLIPOPROTEIN B-100; ATORVASTATIN CALCIUM; BIOMARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PYRROLES; RISK FACTORS;

EID: 84933059481     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.01.050     Document Type: Article

References (38)

1. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 2014;9:73-102.
2. Miller YI, Choi SH, Wiesner P, et al. Oxidationspecific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011;108: 235-48.
3. van Dijk RA, Kolodgie F, Avandia A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53: 2773-90.
4. Lee S, Baranov KG, Romanoski CE, Springstead JR, Luis AJ, Berliner JA. Role of phospholipid oxidation products in atherosclerosis. Circ Res 2012;111:778-99.
5. Kadl A, Sharma PR, Chen W, et al. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Rad Biol Med 2011;51: 1903-9.
6. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008;49:2230-9.
7. Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 2013;54:2815-30.
8. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: A biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Med 2011;5:673-94.
9. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation- specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56:946-55.
10. Tsimikas S, Hall JH. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60:716-21.
11. Tsimikas S, Duff GW, Berger PB, et al. Proinflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol 2014;63: 1724-34.
12. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 2002;277:7010-20.
13. Choi SH, Yin H, Ravandi A, et al. Polyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages. PLoS One 2013;8:e83145.
14. Ravandi A, Leibundgut G, Hung MY, et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol 2014;63: 1961-71.
15. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
16. Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One 2014;9: E114519.
17. Tsimikas S, Willeit P, Willeit J, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 2012;60:2218-29.
18. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidizedphospholipids onapolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009;119: 1711-9.
19. Leibundgut G, Witztum JL, Tsimikas S. Oxidation- specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol 2013;13: 168-79.
20. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36- TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010;12:467-82.
21. Wiesner P, Tafelmeier M, Chittka D, et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res 2013;54:1877-83.
22. Purushothaman KR, Purushothaman M, Levy AP, et al. Increased expression of oxidationspecific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol 2012;60:112-9.
23. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-70.
24. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): shortterm and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004; 109:3164-70.
25. Tsimikas S, Aikawa M, Miller FJ Jr., et al. Increased plasma oxidized phospholipid: Apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: A potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol 2007; 27:175-81.
26. Faghihnia N, Tsimikas S, Miller ER, Witztum JL, Krauss RM. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res 2010;51: 3324-30.
27. Silaste ML, Rantala M, Alfthan G, et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein( a). Arterioscler Thromb Vasc Biol 2004; 24:498-503.
28. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. J Am Coll Cardiol 2006;47:1803-10.
29. Tsimikas S, Witztum JL, Miller ER, et al. Highdose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110:1406-12.
30. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008;51:1653-62.
31. Choi SH, Prasad A, Tsimikas S. The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents. J Am Coll Cardiol 2008;51:2228-9.
32. Fraley AE, Schwartz GG, Olsson AG, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 2009;53:2186-96.
33. Yoshida H, Shoda T, Yanai H, et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 2013;226:161-4.
34. Budoff MJ, Ahmadi N, Gul KM, et al. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial. Prev Med 2009;49:101-7.
35. Ahmadi N, Tsimikas S, Hajsadeghi F, et al. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol 2010;105:459-66.
36. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57:1611-21.
37. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein (a) reduces plasma lipoprotein(a) Levels. Lancet 2015;In press.
38. Bertoia ML, Pai JK, Lee JH, et al. Oxidationspecific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 2013;61:2169-79.